The oral drug cleared by the Drugs Controller General of India (DCGI) on May 1 for emergency use, is an adjunct therapy to treat severe COVID-19 patients. The 2-DG drug has been developed by the Institute of Nuclear Medicine and Allied Sciences, a lab of the DRDO. The 2-DG COVID-19 drug is expected to be launched by mid-June. Ahead of its release, the DRDO listed a set of guidelines to follow while administering the drug to the COVID-19 patients under the care and prescription of doctors. 2DG should be prescribed as early as possible by doctors for moderate to severe COVID-19 patients for a maximum duration of up to 10 days.

Source: dna June 01, 2021 08:26 UTC